Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone818-629-2256
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees39
Next Earnings Date8/22/2019 (Estimated)
OptionableNot Optionable
Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions
What is Sienna Biopharmaceuticals' stock symbol?
Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."
How were Sienna Biopharmaceuticals' earnings last quarter?
Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) issued its quarterly earnings results on Thursday, March, 14th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.10. View Sienna Biopharmaceuticals' Earnings History.
When is Sienna Biopharmaceuticals' next earnings date?
What price target have analysts set for SNNA?
3 Wall Street analysts have issued 1 year target prices for Sienna Biopharmaceuticals' shares. Their predictions range from $17.00 to $45.00. On average, they expect Sienna Biopharmaceuticals' stock price to reach $31.00 in the next year. This suggests a possible upside of 3,727.2% from the stock's current price. View Analyst Price Targets for Sienna Biopharmaceuticals.
What is the consensus analysts' recommendation for Sienna Biopharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sienna Biopharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sienna Biopharmaceuticals.
Has Sienna Biopharmaceuticals been receiving favorable news coverage?
News stories about SNNA stock have trended negative on Sunday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sienna Biopharmaceuticals earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Sienna Biopharmaceuticals.
Are investors shorting Sienna Biopharmaceuticals?
Sienna Biopharmaceuticals saw a drop in short interest in July. As of July 31st, there was short interest totalling 115,500 shares, a drop of 47.9% from the June 30th total of 221,800 shares. Based on an average trading volume of 185,100 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.6% of the company's shares are sold short. View Sienna Biopharmaceuticals' Current Options Chain.
Who are some of Sienna Biopharmaceuticals' key competitors?
Some companies that are related to Sienna Biopharmaceuticals include Fortress Biotech (FBIO), MEI Pharma (MEIP), Tocagen (TOCA), Checkpoint Therapeutics (CKPT), Scpharmaceuticals (SCPH), Eton Pharmaceuticals (ETON), Entasis Therapeutics (ETTX), AgeX Therapeutics (AGE), Avenue Therapeutics (ATXI), Verastem (VSTM), Chembio Diagnostics (CEMI), Aquinox Pharmaceuticals (AQXP), Processa Pharmaceuticals (PCSA), Iterum Therapeutics (ITRM) and Kezar Life Sciences (KZR).
What other stocks do shareholders of Sienna Biopharmaceuticals own?
Who are Sienna Biopharmaceuticals' key executives?
Sienna Biopharmaceuticals' management team includes the folowing people:
- Dr. Frederick C. Beddingfield III, CEO, Pres & Director (Age 54)
- Mr. Timothy K. Andrews Esq., Gen. Counsel & Corp. Sec. (Age 40)
- Mr. Alexander Azoy, CFO & Controller (Age 43)
- Mr. Majed Kheir, VP of Operations (Age 41)
- Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 49)
When did Sienna Biopharmaceuticals IPO?
(SNNA) raised $64 million in an initial public offering on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets acted as the underwriters for the IPO.
Who are Sienna Biopharmaceuticals' major shareholders?
Sienna Biopharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.09%), Victory Capital Management Inc. (2.47%), Morgan Stanley (2.38%), Renaissance Technologies LLC (1.92%), Northern Trust Corp (0.64%) and BlackRock Inc. (0.37%). Company insiders that own Sienna Biopharmaceuticals stock include Dennis M Fenton, Robert J More and Todd Harris. View Institutional Ownership Trends for Sienna Biopharmaceuticals.
Which institutional investors are selling Sienna Biopharmaceuticals stock?
Which institutional investors are buying Sienna Biopharmaceuticals stock?
SNNA stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Paloma Partners Management Co, Jane Street Group LLC, Canada Pension Plan Investment Board, Citadel Advisors LLC and A.R.T. Advisors LLC. View Insider Buying and Selling for Sienna Biopharmaceuticals.
How do I buy shares of Sienna Biopharmaceuticals?
Shares of SNNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sienna Biopharmaceuticals' stock price today?
One share of SNNA stock can currently be purchased for approximately $0.81.
How big of a company is Sienna Biopharmaceuticals?
Sienna Biopharmaceuticals has a market capitalization of $25.04 million. The company earns $-73,470,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Sienna Biopharmaceuticals employs 39 workers across the globe.View Additional Information About Sienna Biopharmaceuticals.
What is Sienna Biopharmaceuticals' official website?
How can I contact Sienna Biopharmaceuticals?
Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]
MarketBeat Community Rating for Sienna Biopharmaceuticals (NASDAQ SNNA)
MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe SNNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
